Literature DB >> 2860225

A new method for studying cell growth in suspension, and its use to show that indomethacin enhances cell killing by methotrexate.

J D Gaffen, A Bennett, M R Barer.   

Abstract

Microturbidimetry has been used to measure the growth of cells in suspension. Disaggregated mouse NC carcinoma cells in culture medium were added to the wells of a microtitre test plate and incubated. Absorbance of 600 nm light was measured daily for 4 days using a microplate reader. As the cells grew, light absorbance increased. Methotrexate 2-40 ng ml-1 reduced cell growth; this effect was increased by indomethacin 1 microgram ml-1, possibly by displacing methotrexate from its binding by serum protein or by enhancing cell uptake of methotrexate. Similar results were obtained by conventional clonogenic assays. The new technique offers simplicity, better reproducibility, and substantial savings in time and cost.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2860225     DOI: 10.1111/j.2042-7158.1985.tb05056.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  4 in total

1.  Studies on the mechanism by which indomethacin increases the anticancer effect of methotrexate.

Authors:  A Bennett; J D Gaffen; P B Melhuish; I F Stamford
Journal:  Br J Pharmacol       Date:  1987-05       Impact factor: 8.739

2.  The effect of folate on the methotrexate/indomethacin interaction in a murine cancer cell line.

Authors:  S J Hollingsworth; E M Anderson; A Bennett
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

3.  Interaction between methotrexate and indomethacin on a human normal haemopoietic cell line.

Authors:  S J Hollingsworth; N P Shankley; E M Anderson; A Bennett
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

4.  Changes in tissue fatty acid composition in murine malignancy and following anticancer therapy.

Authors:  Z Yazici; I A Tavares; I F Stamford; P M Bishai; A Bennett
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.